Startseite
Kongressberichte 2021
ESMO Congress 2021
Saturday, September 18
Mini oral sessions
Genitourinary tumours, non-prostate
Genitourinary tumours, non-prostate
654MO
A phase 2 prospective trial of frontline Cabozantinib in metastatic collecting ducts renal cell carcinoma: the BONSAI trial (Meeturo 2)
Procopio, et al.
Conclusions
The study met its primary endpoint showing promising efficacy and acceptable tolerability of cabo in mCDC pts. Mature results according to mutational profiles and gene signatures will be presented.
655MO
A prospective phase II trial of cabazitaxel in male patients with chemotherapy pre-treated metastatic germ-cell tumors: the CABA-GCT study
Baciarello, et al.
Conclusions
CABA can be safely administered in men with refractory NSGCT and it has modest and similar activity to other drugs used in monotherapy in this setting.
656MO
Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2_ (HIF-2_) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
D.F. McDermott, et al.
Conclusions
In this preliminary analysis, belzutifan plus cabozantinib had manageable safety and showed promising antitumor activity in previously treated pts with advanced ccRCC.
657MO
Antibiotic (ATB) therapy and outcome from Nivolumab (N) in metastatic Renal Cell Carcinoma (mRCC) patients (pts): Results of the GETUG-AFU 26 NIVOREN Multicentric Phase II Study.
Derosa, et al.
Conclusions
ATB severely compromise OS and PFS in N-treated mRCC pts. We confirm the potential deleterious effect for ATB in pts treated with anti-PD1, and the suspected impact of microbiota lay the ground for interventional study.
658MO
Cisplatin (cis)-related immunomodulation and efficacy with atezolizumab (atezo) + cis- vs carboplatin (carbo)-based chemotherapy (chemo) in metastatic urothelial cancer (mUC)
M.D. Galsky, et al.
Conclusions
PD-L1 IC 2/3 status is associated with longer OS in cis- but not carbo-treated pts with mUC. Cis, vs carbo, is associated with increased TNFα-mediated proinflammatory signalling in circulating immune cells and the TME. Together these data suggest that cis/gem induces immunogenic cell death and enhances antitumour immunity, particularly when combined with atezo.
659MO
Avelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)
Martinez Chanza, et al.
Conclusions
Interim results from the AURA phase II trial demonstrate a high pCR rate with neoadjuvant avelumab in combination with each cisplatin-based NAC regimen. Further results in cisplatin eligible/ineligible cohorts and correlative studies will be presented.
LBA31
High- vs low-dose pre-operative ipilimumab and nivolumab in locoregionally advanced urothelial cancer (NABUCCO cohort 2)
Van Dorp, et al.
Conclusions
We observed a pCR in 6/14 (43%) evaluable pts treated with ipi 3 + nivo 1 (arm A). In contrast, a pCR was observed in 1/14 (7%) evaluable pts treated with ipi 1 + nivo 3 (arm B). Our data suggest that ipi 3 + nivo 1 is more efficacious than ipi 1 + nivo 3 as pre-operative treatment in stage III UC. Data for toxicity are added in the presentation.